Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.00.

CADL has been the topic of several recent analyst reports. Citigroup lowered their price target on Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Stephens reissued an “overweight” rating and issued a $15.00 target price on shares of Candel Therapeutics in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, January 21st. Zacks Research cut shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Finally, Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

Candel Therapeutics Price Performance

NASDAQ:CADL opened at $5.25 on Friday. Candel Therapeutics has a 52-week low of $4.25 and a 52-week high of $9.13. The company has a market cap of $288.23 million, a P/E ratio of -9.21 and a beta of -0.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.25 and a current ratio of 8.25. The stock’s 50-day simple moving average is $5.76 and its 200 day simple moving average is $5.50.

Insider Buying and Selling

In other Candel Therapeutics news, Director Paul B. Manning purchased 550,458 shares of the stock in a transaction on Monday, February 23rd. The shares were purchased at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the completion of the transaction, the director directly owned 2,763,527 shares in the company, valued at $15,061,222.15. This represents a 24.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its holdings in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after acquiring an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after purchasing an additional 7,527 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Candel Therapeutics in the fourth quarter valued at $51,000. Invesco Ltd. bought a new position in shares of Candel Therapeutics in the first quarter valued at about $59,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Candel Therapeutics during the 4th quarter worth about $59,000. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.